

Supplemental Figure for:
Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2-advanced breast cancer

Gregory L. Price et al.

Supplemental Figure 1. Incidence of Grade 2 and Grade 3 investigator-assessed diarrhea by cycle and treatment. Grades established by the National Cancer Institute¹: Grade 1: increase from a patient's own baseline of less than 4 stools a day; Grade 2: increase from patient's own baseline of 4 to 6 stools a day; Grade 3: requires treatment in the hospital or clinic, characterized by several factors, like the increase of 7 or more stools a day, inability to control bowel movements, and reduced ability to care for daily needs; Grade 4 – life-threatening condition requiring immediate intensive care. There were no diarrhea events Grade ≥ 3 observed in this study.

1. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

Supplemental Figure 1. Goetz et al, Top

